Search results for "Ulcerative"

showing 10 items of 294 documents

Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammator…

2021

Patients with long-standing colonic inflammatory bowel disease (cIBD) are at increased risk of developing colorectal cancer (CRC). Dye-spray chromoendoscopy (DCE) with targeted biopsies is the preferred technique for surveillance of dysplasia. Virtual chromoendoscopy (VCE) are arising to improve detection rates and adherence to surveillance guidelines, although its role is not yet well defined. The purpose of this study is to assess the effectiveness of VCE with iSCAN as an alternative method for dysplasia detection in cIBD.Retrospective case-control study with 191 patients included, 98 in the DCE (Indigo carmine) group and 93 in the VCE (iSCAN, twin-mode 1-3) group. The dysplasia detection…

medicine.medical_specialtyColorectal cancerColonoscopyInflammatory bowel diseaseGastroenterologyChromoendoscopy03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansColoring Agentsskin and connective tissue diseasesEarly Detection of CancerRetrospective StudiesAlternative methodsmedicine.diagnostic_testbusiness.industryGastroenterologyCase-control studyColonoscopyInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesIncreased riskDysplasiaCase-Control Studies030220 oncology & carcinogenesisColitis Ulcerative030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessScandinavian Journal of Gastroenterology
researchProduct

Mesalazine for the treatment of inflammatory bowel disease

2013

Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combinin…

medicine.medical_specialtyColorectal cancerDiseaseGastroenterologyInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseMesalazineInternal medicineSecondary PreventionmedicineHumansPharmacology (medical)Intestinal MucosaColitisMesalaminePharmacologyCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicinemedicine.diseaseUlcerative colitischemistryTolerabilityColitis UlcerativeColorectal NeoplasmsbusinessExpert Opinion on Pharmacotherapy
researchProduct

The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?

2016

Sir, We read with interest the recent work by Peyrin-Biroulet and colleagues on the long-term outcome for patients starting anti-TNF monotherapy for Crohn’s disease [CD] and for those needing the addition of an immunomodulator [IM].1 We agree with the main finding of the study, i.e. starting with anti-TNF monotherapy does not worsen long-term disease outcomes. This is in line with data from the literature2 and with our recent prospective study on the concomitant use of an IM and infliximab [IFX] in patients with CD or ulcerative colitis who have had a primary or secondary non-response to IFX monotherapy3: …

medicine.medical_specialtyCombination therapyDiseaseInflammatory bowel diseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunologic FactorsTreatment FailureProspective cohort studyCrohn's diseasebusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInfliximabInfliximab030220 oncology & carcinogenesisConcomitantImmunology030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drugJournal of Crohn'scolitis
researchProduct

Response to "The combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous An…

2018

medicine.medical_specialtyCombination therapymedicine.drug_class030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedGastroenterologyVedolizumab03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicinemedicineHumansColitisHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologymedicine.diseaseUlcerative colitisCytapheresisMonoclonalCorticosteroidTumor necrosis factor alphaColitis UlcerativebusinessCytapheresis030215 immunologymedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

HLA-DQ: Celiac diseasevsinflammatory bowel disease

2018

Aim To determine the genetic predisposition to celiac disease (CeD) in inflammatory bowel disease (IBD) patients by quantifying the frequency of CeD-related human leucocyte antigen (HLA) (HLA-CeD: HLA-DQ2 and -DQ8) in IBD patients globally, by type of IBD and gender, and by calculating the protective/risk contribution of these haplotypes in the development of the IBD disease. Methods We conducted a prospective study with IBD patients from our Unit. Clinical information was gathered and blood was tested for HLA-CeD. The control group was made up of unrelated Valencian organ donors. Results 1034 subjects were analyzed: 457 IBD [207 ulcerative coliti (UC) and 250 Crohn's disease (CD)] patients…

medicine.medical_specialtyCrohn's diseaseHLA-DQB1business.industryGastroenterologynutritional and metabolic diseasesGeneral MedicineHuman leukocyte antigenmedicine.diseaseGastroenterologyInflammatory bowel diseaseUlcerative colitis03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineHLA-DQGenetic predispositionMedicine030211 gastroenterology & hepatologybusinessProspective cohort studyWorld Journal of Gastroenterology
researchProduct

P145 Inflammatory Bowel Disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: resu…

2021

Abstract Background Little is known regarding the outcomes of inflammatory bowel disease (IBD) patients who required surgery during the outbreak of Coronavirus disease 19 (COVID-19). This study aimed to compare outcomes of IBD patients undergoing surgery in COVID-19-treatment and COVID-19-free hospitals. Methods Retrospective study involving patients undergoing IBD surgery in seven centres (six COVID-19-treatment hubs and one COVID-free hospital) across 5 European countries during the period of highest reduction of elective activity due to the first peak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Predictive variables of the risk of moderate-to-severe postope…

medicine.medical_specialtyCrohn's diseaseReferralbusiness.industryGastroenterologyOutbreakGeneral MedicineDiseasemedicine.diseaseClinical: Diagnosis and OutcomeComorbidityUlcerative colitisInflammatory bowel diseasePoster presentationsSurgeryIntensive caremedicinebusinessAcademicSubjects/MED00260Journal of Crohn's and Colitis
researchProduct

Pulmonary function abnormalities in respiratory asymptomatic patients with inflammatory bowel disease

2002

BACKGROUND: There is evidence that pulmonary function abnormalities are present in patients with inflammatory bowel disease (IBD). The aim of this crossover study was to assess the frequency of pulmonary dysfunction in patients with IBD and to define the importance of possible confounding factors. METHODS: We investigated a total of 44 patients with Crohn's disease or ulcerative colitis and no pulmonary symptoms or a history of respiratory diseases by means of pulmonary function testing and chest X-ray. As controls we examined 44 healthy subjects matched for gender, age, and smoking status. RESULTS: A total of 21% of the subjects with ulcerative colitis and 20% with Crohn's disease showed a…

medicine.medical_specialtyCrohn's diseasebusiness.industryDiseasemedicine.diseaseCrossover studyAsymptomaticGastroenterologyUlcerative colitisInflammatory bowel diseasedigestive system diseasesPulmonary function testingInternal medicineInternal MedicineMedicineRespiratory systemmedicine.symptombusinessEuropean Journal of Internal Medicine
researchProduct

P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, inte…

2020

Abstract Background Prevalence of NAFLD has recently been reported increased in inflammatory bowel disease (IBD) with conflicting results due to heterogeneity of published studies, especially in the diagnostic definition of NAFLD. The increased risk of NAFLD might be related to traditional risk factors but also to IBD-related factors. The role of genetic markers has been addressed only in one study. The aim of our study has been to assess the prevalence of NAFLD and fibrosis in a homogeneous cohort of patients with IBD, assessing the role of metabolic, disease-related and genetic factors. Methods the diagnosis of NAFLD was based on transient fibroelastometry findings (CAP ≥288 dB/m) and HSI…

medicine.medical_specialtyCrohn's diseasebusiness.industryFatty liverGastroenterologySingle-nucleotide polymorphismInflammationGeneral MedicineDiseasemedicine.diseaseInflammatory bowel diseaseGastroenterologyUlcerative colitisdigestive system diseasesFibrosisInternal medicinemedicinemedicine.symptombusinessJournal of Crohn's and Colitis
researchProduct

P275 Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Span…

2018

medicine.medical_specialtyCrohn's diseasemedicine.diagnostic_testbusiness.industryColorectal cancermedicine.medical_treatmentGastroenterologyColonoscopyGeneral MedicineJaundiceLiver transplantationmedicine.diseaseUlcerative colitisInflammatory bowel diseaseTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMedicine030211 gastroenterology & hepatologymedicine.symptombusinessJournal of Crohn's and Colitis
researchProduct

Chemically induced mouse models of colitis.

2012

Crohn's disease (CD) and ulcerative colitis (UC), both of which are referred to as inflammatory bowel disease (IBD), are chronic inflammatory disorders of the gastrointestinal tract that have characteristic clinical, pathological, endoscopic, and radiologic features. Knowledge about the pathogenesis of IBD has dramatically increased in recent years based in part on the use of experimental models of IBD. Although none of these models exactly mimics the human disorder, they have proven to be useful for studying many important aspects of these conditions. Detailed in this unit is a description of the most commonly used chemically induced mouse models of IBD. These include trinitrobenzene sulfo…

medicine.medical_specialtyDiseasedigestive systemInflammatory bowel diseaseGastroenterologyOxazolonePathogenesischemistry.chemical_compoundMiceInternal medicinemedicineAnimalsColitisAnimal HusbandryPathologicalPharmacologyGastrointestinal tractbusiness.industryDextran SulfateOxazolonemedicine.diseaseColitisUlcerative colitisdigestive system diseasesDisease Models AnimalchemistryTrinitrobenzenesulfonic AcidImmunologybusinessCurrent protocols in pharmacology
researchProduct